UB researchers have identified a key molecule in insulin resistance, a condition that favours the development of type 2 diabetes. The study, published in the science journal Metabolism. Clinical and Experimental, shows how the enzyme BACE1 and its product, soluble APPβ, are involved in the breaking out of the inflammatory process and insulin resistance. These results were obtained in mice and open the doors to the development of new drugs to treat this type of diabetes.
The study is led by the team led by the lecturer Manuel Vázquez Carrera, member of the Unit of Pharmacology, Therapeutics and Pharmacognosy of the Faculty of Pharmacy and Food Sciencesand the Institute of Biomedicine (IBUB) of the UB, as well as member of the Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre(CIBERDEM). The following experts have also taken part in the study: Dolors Serra and Laura Herrero, from the Faculty of Pharmacy and Food Sciences and IBUB; Anna Gumà, from the Faculty of Biology and IBUB; Joan Vendrell and Sònia Fernández, from Pere i Virgili Institute and CIBERDEM, and other experts from the University of Dundee (United Kingdom).
